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Abstract: Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of 
olanzapine which disintegrates in saliva almost immediately, developed as a convenient and 
adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical   studies, 
which form the basis of this review, have shown ODO and SOT to have similar efficacy and 
tolerability profiles. However, ODO appears to have a number of advantages over SOT in 
terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing 
clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, 
agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and 
greater patient preference, may also be an appropriate formulation for the majority of patients 
for which olanzapine is the antipsychotic of choice.
Keywords: orodispersible formulation, orally disintegrating, olanzapine, atypical   antipsychotics, 
patient adherence, preference, schizophrenia, bipolar disorder
Introduction
Olanzapine is an efficacious and well-tolerated atypical antipsychotic indicated for the 
treatment of schizophrenia and acute manic or mixed episodes, along with maintenance 
therapy in bipolar disorder and (in some countries) related psychiatric disorders.1–3 
Consistent with the findings from large comparative clinical trials and observational 
studies,4–8 olanzapine has been found to be comparable or superior to other atypical 
antipsychotic medications in meta-analyses of head-to-head studies using a variety of 
efficacy/effectiveness and safety/tolerability outcomes.1,2 Notwithstanding potential 
weight gain as an important consideration associated with olanzapine treatment, this 
medication has a favorable risk/benefit profile that has led to it being extensively 
utilized worldwide.9
In order to optimize the utility of olanzapine in patient groups with different 
needs and preferences, a number of formulations have been developed. In addition to 
short- and long-acting injectable formulations, olanzapine is commercially available 
in two primary oral dosage forms, standard olanzapine-coated tablets (SOT) and orally 
disintegrating olanzapine (ODO; otherwise known as orodispersible tablets [ODT]). 
Oral olanzapine is also available as granules in Japan. SOT is marketed under the trade 
name Zyprexa® and ODO under the name Zyprexa® Zydis® (where “Zydis” refers to 
the patented freeze-dried orodispersible technology of Catalent Pharma Solutions, 
Somerset, NJ) or Zyprexa® Velotab™ (in Europe). The majority of clinical studies 
concerning the efficacy/effectiveness, safety, and health outcomes associated with 
olanzapine treatment have been conducted with SOT. With few exceptions mentioned 
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in this review, almost all randomized controlled trials (RCTs) 
of olanzapine have used SOT.
Although liquid and injectable (rapid-acting and long-
acting depot) antipsychotics are alternatives to standard 
tablets in various clinical situations, for example in the 
acute setting or where patients have adherence issues, these 
formulations have limitations. Patients may spit out liquid 
medication or find injectable medication unacceptable or 
contraindicated. Despite the clinical utility of olanzapine in 
standard tablet form (ie, SOT), this formulation also has a 
number of limitations inherent to all standard tablets in the 
treatment of chronic mental illness. These include admin-
istration in situations where the patient is acutely agitated, 
use in patients with concomitant medical conditions where 
there is difficulty in swallowing, taste which some patients 
may find disagreeable, or the need for fluids to ingest which 
may not be available and may draw unwanted attention to 
the patients’ condition. Most importantly, treatment nonad-
herence (particularly surreptitious/deliberate avoidance) is 
a major problem in patients with mental illnesses such as 
schizophrenia. Up to 80% of patients are at least partially 
nonadherent to antipsychotic treatment at some point dur-
ing their illness,10 which is, in turn, a leading contributor to 
treatment failure, relapse, and hospitalization.1,11,12 Moreover, 
given the patient population, which often includes persons 
with limited insight into their illness, any measures that 
may help enhance palatability or acceptance of medication 
is likely to aid treatment adherence and persistence and 
improve long-term outcomes for the patient. Thus, although 
rapid-acting intramuscular formulations are effective, for 
example in treating acutely agitated patients, oral medica-
tions can be used in this situation and have been shown to 
be preferred by patients.13 A number of treatment guidelines 
for the management of acutely agitated and aggressive 
patients recommend that the oral route of administration is 
preferred and that oral antipsychotics like SOT and ODO, 
with or without benzodiazepines, be considered prior to the 
use of intramuscular antipsychotic formulations.14,15 As oral 
treatments are less invasive than injections, this is consistent 
with the need to establish a good initial therapeutic alliance 
that predicts a positive attitude towards medication, which 
in turn predicts adherence.16
To some extent, as with liquid formulations of antipsy-
chotics, a palatable and effective rapidly-disintegrating oral 
formulation which cannot be sequestered (“cheeked”) for later 
expulsion (in other words, for which ingestion can be   verified) 
may overcome some or all of the difficulties associated 
with standard tablets and injectables in individual patients. 
Thus, ODO (at least in Zydis form) provides the benefits of 
a liquid medication in a solid dosage form and is the reason 
ODO was developed. Prescription data in the UK supports the 
proposition that ODO may be used as an alternative to depot 
formulations in patients with adherence issues.17 Analysis of a 
number of recent trials in patients with schizophrenia, where 
the clinician was given the option of prescribing ODO or 
SOT, show that ODO was preferentially used in patients who 
were sicker/more acutely ill (see below). It should be noted 
that other nonproprietary (generic) orally dissolving formu-
lations of olanzapine, which consist of loosely-compressed 
rather than lyophilized wafers, are marketed in a number 
of countries around the world. However, unless otherwise 
specified, ODO referred to in this article is the proprietary 
Zyprexa Zydis/Velotab forms manufactured through freeze-
dried technology and marketed by Eli Lilly and Company 
(Indianapolis, IN).
The purpose of this article is to provide an overview of 
ODO characteristics and review the available data on its 
clinical utility (physical properties, effectiveness, safety, 
adherence, nursing burden, and preference), particularly 
on the basis of recent studies. For a comprehensive review 
of earlier ODO studies, the reader is also referred to the 
review article by San et al.18 All studies of ODO uncov-
ered from a PubMed search (as at November 8, 2011; 
English language articles only) using the terms “orally 
disintegrating olanzapine,” “orally dissolving   olanzapine,” 
“  orodispersible olanzapine,” “zyprexa zydis,” “ODT 
  olanzapine,” “ODO olanzapine,” and “velotab” and refer-
ences therein, as well as currently unpublished Eli Lilly-
sponsored studies, were considered for inclusion in this 
review if they were of reasonable sample size and of sufficient 
rigor in design to allow meaningful interpretation.
ODO characteristics
A number of orally disintegrating tablet or wafer formulations 
have recently been developed with the advantage of dissolv-
ing rapidly in the oral cavity without the need for liquids19 
and masking the taste of the medication.20 It is to this class 
of medication delivery product that ODO belongs. Produced 
by freeze-drying through the Zydis method, ODO consists of 
olanzapine as the active ingredient entrapped within a matrix 
of fast-dissolving carrier material.21 It is administered by 
placing it on the tongue, where it rapidly disintegrates.
ODO tablets are yellow, round, and debossed with the tab-
let strength. Each ODO tablet contains the olanzapine equiva-
lent of 5 mg (16 µmol), 10 mg (32 µmol), 15 mg (48 µmol), 
or 20 mg (64 µmol). ODO also contains the   following 
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inactive ingredients: gelatin, mannitol,   aspartame, sodium 
  methylparaben, and sodium propylparaben.   Phenylalanine 
(0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20 mg ODO 
tablet, respectively) is also included (US prescribing informa-
tion available from: http://pi.lilly.com/us/zyprexa-pi.pdf).
ODO tablets dissolve in human saliva in seconds. For 
example, in a pilot study of eleven patients, where the first 
measured time points were 15 seconds for initial disinte-
gration and 60 seconds for complete disintegration, Chue 
et al found that the mean time to initial disintegration was 
15.78 seconds and mean time to complete disintegration was 
0.97 minutes.22 As some medications in orally disintegrat-
ing formulation undergo pregastric absorption (from saliva 
in the mouth, pharynx, and esophagus), bioavailability of 
such orodispersible forms has been found to be considerably 
greater than their standard dosage forms.21 Although oral 
absorption may be enhanced with ODO, this has not been 
found to result in a different pharmacokinetic profile relative 
to SOT. While a number of studies have demonstrated more 
rapid onset of absorption of olanzapine with ODO and earlier 
measurable and higher plasma concentrations within the first 
1–2 hours compared with SOT, the clinical relevance of these 
differences is unclear. It has been suggested that ODO may 
have a faster onset of action and be more appropriate for 
the treatment of acute agitation in schizophrenia or bipolar 
disorder.23 However, ODO was found to be bioequivalent 
to the same dosage of SOT with the maximum observed 
concentration and time taken to reach maximum observed 
concentration being almost indistinguishable between the 
two formulations.23–25 For example, although Bergstrom 
et al found more rapid initial absorption into the blood of 
olanzapine from ODO, the difference in means between ODO 
and SOT for maximum plasma concentration and area under 
the curve of plasma concentration over time were all ,10% 
and the 90% confidence intervals for the ratio of mean values 
were within the standard bioequivalence limits of 0.80–1.25. 
Absorption rate constants for the two formulations have also 
not been found to be considerably different.23
Comparative dissolution
Generic mouth-disintegrating forms of olanzapine are 
manufactured by several different companies using differ-
ent formulations and processes. In a recent in vitro study 
by Hobbs et al, differences in disintegration and dissolu-
tion time of the active ingredient (along with a number of 
other parameters) of twelve types of mouth-disintegrating 
olanzapine tablets (including ODO), along with Risperdal 
M-Tab® as a comparator, were investigated using automated 
dissolution test equipment.26 While this study is the subject 
of a manuscript in preparation and will not be described 
here in detail, ODO disintegrated and dissolved (ie, released 
active ingredient) more rapidly in a solution of synthetic 
saliva than any of the generic tablets. Some of the generic 
tablets were also found to leave a coarse insoluble residue 
from the excipients used. Hobbs et al concluded that these 
different disintegration times, excipient content, and tablet 
residue could influence mouth feel and taste which may in 
turn impact adherence to treatment; however, this assump-
tion has yet to be tested in vivo.
Clinical studies
Effectiveness of a medication takes into consideration a 
variety of factors such as its efficacy and safety, patient 
adherence, and the ease of use for patients. As summarized 
in Table 1, a number of studies have examined these factors 
in relation to ODO and their results will be discussed in 
detail below.
Of the fifteen clinical studies assessing the efficacy/
effectiveness of ODO, two are RCTs: one is a double-blind 
parallel-arm trial assessing the safety of ODO compared 
with SOT as its primary objective27 and the other is an open-
label crossover study assessing patient preference for ODO 
compared with SOT.28 Four observational cohort studies have 
also compared patients taking ODO and SOT.29–32 Addition-
ally, one observational cohort study compared ODO with 
standard oral therapies,13 while others compared ODO with 
risperidone oral solution,33 as well as intramuscular olan-
zapine and haloperidol.34 One small retrospective open-label 
study compared ODO and SOT, with randomization to anti-
psychotic but chronological assignment to ODO or SOT.35 
There are also a number of single-arm studies assessing 
ODO: a small pilot study by Chue et al examined the safety 
and acceptance of ODO in patients already stabilized on 
SOT,22 a 4-week study by Hori et al assessed the efficacy, 
safety, and acceptance of ODO in patients with first-episode 
psychosis,36 a 6-week observational study assessed ODO in 
a French cohort of psychotic patients,37 and a 6-week study 
by Kinon et al examined the efficacy, safety, and acceptance 
of ODO in a population of nonadherent patients.38 A single-
arm retrospective observational study of ODO in Belgium 
has also been conducted.39
Efficacy/effectiveness
The majority of studies investigating the efficacy/effec-
tiveness of ODO have been conducted in patients with 
  schizophrenia spectrum disorders and have used a number of 
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standard clinician-rated instruments as measures of symptom 
improvement – most commonly, the Positive and Negative 
Symptom Scale (PANSS) and its subscales40 and the Clinical 
Global Impression (CGI) scale.41 These studies have been 
conducted as either open-label assessments of ODO alone 
(single-arm studies) or comparison of ODO to SOT, or, in 
a few cases, to other typical and/or atypical antipsychotics 
(comparative studies). The studies from each of these cat-
egories are described separately below.
Single-arm studies
Results from single-arm studies show that following the 
initiation of therapy with ODO, a substantial improvement 
in the symptoms of schizophrenia is observed within a short 
time-frame (,1 week). In the 6-week study of acutely ill, 
previously nonadherent patients (N = 85) conducted by Kinon 
et al,38 patients were started on ODO but could switch to SOT 
after 1 week (24 patients switched to SOT, while 49 patients 
remained on ODO). The study showed a significant improve-
ment in PANSS total score by week 1, which was maintained 
to the end of the study (PANSS total score change to end-
point, last observation carried forward: −24.41, P , 0.001), 
while an improvement in CGI-Improvement score occurred 
between day 2 and week 6 (endpoint 2.74, P , 0.001).
Studying 512 acutely psychotic French patients predomi-
nantly diagnosed with schizophrenia and treated with ODO 
in a hospital setting, Dardennes et al found that the majority 
of patients treated with ODO had been previously poorly 
adherent (51.0%) with a poor attitude towards medication 
or had refused medication (74.6%).37 During this 6-week 
study, PANSS total score decreased (last observation carried 
forward) from 106.9 to 65.7 and the proportion of patients 
reporting being very satisfied with ODO increased from 
22.9% to 29.5%. Statistical significance for these results 
was not reported.37
Van Heeringen et al conducted a retrospective study 
in a cohort of 548 Belgian psychiatric patients diagnosed 
with various conditions, most of whom were not willing 
to take their medication and were agitated (82.1%).39 The 
study aimed to determine if ODO had an impact on nurs-
ing workload or reduced the need for intramuscular drugs 
(thus reducing potential for needle stick injury, reducing the 
amount of patient monitoring, and helping to build the thera-
peutic alliance between patient and healthcare professionals). 
On the day following initiation, significant improvements in 
agitation and degree of cooperation were observed. The most 
common reasons cited for changing to ODO in preference 
to standard tablets were the perception that ODO facilitates 
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controlled intake and is easier to administer to   uncooperative 
patients.
In Hori et al’s study of first-episode schizophrenia patients 
(N = 53) treated with ODO, a significant improvement in 
PANSS-Excited Component (PANSS-EC; comprising excite-
ment, hostility, hallucinatory behavior, uncooperativeness, 
and poor impulse control) score was seen by day 3 and a 
significant improvement in PANSS-Complementary Items 
(comprising anger, difficulty in delaying gratification, and 
mood instability) score was seen by day 7.36 During the 4-week 
study, 71.6% (38/53) of patients had responded (defined 
as $30% reduction in PANSS total score from baseline), not 
including five patients who dropped out. The authors noted 
that the results are consistent with studies which demonstrated 
SOT to be efficacious in the acute treatment of excitement and 
psychomotor agitation associated with schizophrenia.
Comparative studies
Two RCTs27,28 and four prospective cohort studies29–32 com-
pared the efficacy of ODO with SOT. Additionally, one rela-
tively small (N = 38) retrospective open-label study utilized 
chronological sequential assignment of patients to ODO or SOT 
and used PANSS to compare the efficacy of these groups.35 
The results of these studies suggest that improvements, or 
maintenance of improvements, in schizophrenia symptoms 
seen with ODO are similar to those with SOT.27–32,35 Another 
study compared ODO with liquid risperidone.33 These studies 
are discussed in more detail below.
In a conference presentation (not yet published), an Eli 
Lilly-sponsored prospective observational study compared 
ODO and SOT in an Australian cohort (N = 104) of inpatients 
with schizophrenia and related disorders over the first week 
of treatment.29 The study found that ODO was preferentially 
prescribed to noncompliant patients (83% of ODO patients 
versus 55% of SOT patients). However, in contrast to other 
observational studies described below, there was no evidence 
that ODO was prescribed more often to more severely ill 
patients in this study. While significant improvements were 
observed in both groups over 1 week in all effectiveness 
measures (PANSS-negative symptoms, PANSS-EC, and 
CGI-Severity [CGI-S] scale), no significant differences were 
observed between the groups. This suggests that in a routine 
inpatient setting, the effectiveness of SOT and ODO for-
mulations of olanzapine are comparable, even though ODO 
was preferentially prescribed to the more difficult-to-treat 
nonadherent patient group.
Czekalla et al investigated the effectiveness of ODO 
compared with SOT in a 2-week prospective observational 
study of 456 patients predominantly with schizophrenia, 
schizotypal, or delusional disorder (80.3%).30 Clinical 
improvements (CGI-Improvement) in both formulation 
groups were similar with improvements in 91.8% of the ODO 
group compared with 92.3% in the SOT group.   However, 
as pointed out by Czekalla et al, interpretation of these data 
should take into consideration the higher proportion of 
severely ill patients (ODO: 64.4%; SOT: 49.8%) and patients 
displaying externally-directed aggression (ODO: 37.7%; 
SOT: 16.4%), who may be more difficult to treat, in the 
ODO cohort. Additionally, around 50% of patients overall 
received relatively high doses of olanzapine ($20 mg/day) 
by the end of the observation period, particularly in the ODO 
group (59.1%).
Pascual et al’s naturalistic study compared ODO with 
conventional oral antipsychotic medication (mostly halo-
peridol) over 6 hours in the treatment of 80 acutely agitated 
patients with psychotic disorders in an emergency department 
setting.13 In such a setting, any advantage may keep both 
healthcare providers and patients safer from the consequences 
of aggression. While both groups had statistically significant 
improvements from baseline in PANSS-EC, a significant 
difference favoring ODO was observed at 1 hour (but not 
thereafter). Significant improvement overall from baseline 
was also seen in Agitation Calmness Evaluation Scale scores 
for both groups, but not between groups at any time point 
up to 6 hours. Although there was no significant difference 
in the proportion of patients in each group requiring physi-
cal restraint, more patients receiving ODO (70%) did not 
require a second medication compared with the conventional 
antipsychotic treatment group (50%; P = 0.04). However, as 
discussed in a later section, it is important to bear in mind 
the nonsignificance of secondary comparisons, which may 
be underpowered, should be interpreted with caution, and 
should not necessarily imply equivalence.
A posthoc analysis of a prospective open-label study 
by Arranz et al measured core symptom improvement in 
never-treated first-episode psychotic patients chronologically 
assigned to either ODO or SOT for 6 weeks (19 patients in 
each group).35 Relative to baseline, a significant decrease 
in PANSS total score was observed in both groups (mean 
decrease of 33.4 ± 20 in the SOT group and 36.6 ± 19 in the 
ODO group). However, treatment type was not found to have 
a significant effect on change in PANSS score.
To date, only two head-to-head studies comparing ODO 
with another antipsychotic have been conducted. Hatta et al 
evaluated the efficacy and tolerability of ODO compared 
with risperidone oral solution in Japanese acutely agitated 
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psychotic patients over a short duration (1 hour).33 The design 
of this study was somewhat unusual in its use of a pseudoran-
domization protocol where patients were allocated (chrono-
logically) to ODO in the first month of recruitment and 
risperidone oral solution in the second month of recruitment, 
or to the equivalent antipsychotic if it had worked well for 
them previously. Patients were subsequently followed up in a 
relatively naturalistic way. No significant difference between 
the treatments groups was seen in improvement in clinical 
symptomatology as assessed by change in PANSS-EC or 
CGI-S. Nor was there any significant difference between 
the groups in the proportion of patients requiring a “rescue” 
intramuscular treatment due to worsening. No significant dif-
ferences in patient satisfaction with treatment were observed. 
Thus, similar efficacy between the two treatments in the acute 
setting in this patient population was concluded.
In a similar study of agitated psychotic patients at an 
acute care psychiatric ward in Taiwan, Hsu et al followed 
42 patients for 24 hours after random allocation to either 
ODO, intramuscular olanzapine, risperidone oral solution, 
or intramuscular haloperidol. They found that these treat-
ments were similarly effective in the treatment of agitation 
over 24 hours based on a number of measures (PANSS-EC, 
Agitation Calmness Evaluation Scale, and CGI-S).   However, 
they found that ODO and intramuscular olanzapine (but 
not risperidone oral solution) were more effective than 
intramuscular haloperidol in the early phase of treatment 
(up to 90 minutes) based on PANSS-EC. Moreover, while 
not statistically significant, ODO produced slightly more 
improvement, based on PANSS-EC, in this small sample 
than intramuscular olanzapine within the first hour.34
Kuramochi et al assessed a cohort of 1068 schizophrenia 
patients from a 6-week Japanese noninterventional study of 
olanzapine in which patients were stratified by formulation 
initially prescribed (ODO or SOT).31 They found that while 
ODO treatment was associated with a significantly shorter 
duration of illness (16.3 versus 18.4 years) and more severe 
acute phase symptoms for the current episode, positive symp-
toms of schizophrenia improved significantly over 6 weeks 
and to a similar degree regardless of which formulation was 
initially prescribed.
In the only randomized double-blind clinical trial compar-
ing ODO and SOT, Karagianis et al administered ODO sub-
lingually in a double-dummy fashion (that is, active standard 
tablet plus placebo ODT or placebo standard tablet plus active 
ODT) in order to preserve blinding to the active   formulation.27 
Although this study was predominantly designed to investi-
gate the effects of continuing SOT   treatment versus switching 
to ODO on body mass index (BMI) and weight in patients 
who had previously gained weight with SOT, a number of 
efficacy measures were also included in this 16-week study. 
No statistically significant differences between the treatment 
groups were observed in any efficacy measures (CGI-S, 
Global   Assessment of   Functioning scale, and   Subjective 
Wellbeing Under   Neuroleptics scale).   However, it must be 
borne in mind that patients in both groups were clinically 
stable at baseline and so opportunity for   improvement was 
limited.
The other randomized study was a 12-week preference 
study of ODO and SOT in patients with schizophrenia con-
ducted by Bitter et al.28 This study also included CGI-S as 
a measure of efficacy and found no significant difference 
in efficacy between the two formulations (P = 0.87) while 
adjusting for baseline adherence level. However, it should 
be noted that in order to be entered into the study, patients 
had to be stable and tended to have mild to moderate symp-
toms (CGI-S: ODO 2.3; SOT 2.5) which remained stable 
throughout the duration of the study.
The longest comparative study of ODO versus SOT 
(12 months) was conducted by Chartier et al, which evalu-
ated the effectiveness of oral olanzapine formulations in a 
  European cohort (Greece 38%, France 35%, and Germany 
26%) of patients with schizophrenia or bipolar disorder 
treated in a naturalistic setting.32 Patients initially prescribed 
ODO were significantly younger, had a significantly shorter 
history of illness, and were significantly more likely to be 
diagnosed with bipolar disorder. They were also significantly 
more severely ill, irrespective of disease type, and were rated 
significantly less adherent with medication at baseline than 
SOT-treated patients. These factors may explain why patients 
initiated on ODO were prescribed significantly higher 
doses of olanzapine on average (15.0 mg/day) compared 
with patients initiated with SOT (10.6 mg/day). As may 
be expected, ODO tended to be prescribed to patients with 
less insight into their illness, its effects, and need for treat-
ment, suggesting that utilization of the two oral olanzapine 
formulations is associated with different patient profiles. 
However, regardless of indication, patients on ODO formu-
lation experienced significantly greater improvements in 
disease severity, global functioning, and wellbeing (though 
not medication adherence and therapeutic alliance) compared 
with the SOT group.
Safety
As both ODO and SOT contain olanzapine as the active 
ingredient, they were expected to have similar safety and 
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tolerability profiles. Indeed, the tolerability profile seen in 
clinical studies with ODO has been found to be similar to 
the more extensively studied SOT formulation. A number 
of studies of ODO have included measurement of safety 
and tolerability.
Treatment-emergent adverse events (TEAEs)
There are five studies reporting safety information on TEAEs 
with ODO.22,27,28,30,38 In a small pilot study by Chue et al,22 
three of eleven patients had nonserious TEAEs including 
asthenia and insomnia. In a larger study by Kinon et al,38 
TEAEs reported by at least 10% of patients included agi-
tation, dry mouth, headache, insomnia, somnolence, and 
weight gain. However, while quantitatively and qualita-
tively similar to SOT studies, these single-arm studies did 
not allow direct comparisons of the adverse event profile of 
ODO with SOT.
In the 16-week double-blind RCT conducted by   Karagianis 
et al,27 a similar proportion of patients in the SOT treatment 
arm developed TEAEs compared with patients in the ODO 
arm. The most commonly reported adverse events (occurring 
in $5% of patients in either treatment arm) were increased 
appetite, headache, somnolence, fatigue, and   dizziness. Two 
patients in the ODO arm developed serious adverse events, 
including one with dizziness requiring hospitalization and 
one who attempted suicide. As a double-blind trial, this is the 
most appropriate study design to investigate the comparative 
effect of treatment on safety and tolerability.
Adverse events were also assessed in a prospective 
comparative cohort study.30 In this study, 6.5% of patients 
on ODO developed adverse events compared with 2.9% of 
patients on SOT. Half of the adverse events in both arms 
were considered mild (50.0%), while the majority of the 
remaining adverse events were considered moderate (46.4%). 
There were three discontinuations due to adverse events in 
the ODO arm, caused by allergic reaction, increased creatine 
kinase, and restlessness. It is important to keep in mind that 
in this study, both clinicians and patients were aware of 
which treatment patients were taking. This has the potential 
to bias the reported rate of adverse events when new treat-
ments are being used.
In the open-label crossover study by Bitter et al,28 which 
randomized patients to ODO or SOT, no significant differ-
ence was found in the proportion of patients experiencing at 
least one TEAE while treated with either medication (ODO: 
16.8%, SOT: 12.5%; P = 0.31). The most common adverse 
events in the ODO group were weight increase (7.6%), hyper-
triglyceridemia (2.4%), and somnolence (1.6%).
Both randomized studies have thus shown no difference 
between ODO and SOT in terms of frequency of TEAEs,27,28 
while naturalistic studies,30 where treatment decisions are 
made by physicians on the basis of patient characteristics and 
in the course of normal clinical practice in the knowledge 
of the treatment being prescribed, have tended to show a 
higher rate of TEAEs with ODO. As suggested by Czekalla 
et al,30 this may simply reflect baseline differences between 
the treatment groups such as a higher rate of utilization of 
ODO in more severely ill and/or nonadherent patients due 
to its perceived benefits in this population. Such patients 
may, in turn, be prescribed commensurately higher doses of 
olanzapine or concomitant medications, be more prone to 
adverse events, and be more closely monitored or more likely 
to report adverse drug reactions. On the other hand, random-
ization, particularly when combined with blinding to treat-
ment, is designed to negate such imbalances between patient 
characteristics in relation to treatment allocation, allowing for 
more objective comparison of treatment effects. Therefore, 
the differences in the rate of adverse events observed with 
different formulations in open-label naturalistic studies may 
reflect preexisting differences in characteristics of the patient 
groups being compared rather than differences in the safety 
profiles of ODO and SOT.
Extrapyramidal symptoms
Treatment-emergent movement disorders, including 
extrapyramidal symptoms and tardive dyskinesia, are 
associated with a number of antipsychotic medications and 
may have a significant impact on treatment nonadherence 
and discontinuation.42,43 In the single-arm open-label study 
by Kinon et al, significant improvement in extrapyramidal 
symptoms was observed in the ODO-treated patients after 
switching from SOT as measured by the Simpson–Angus 
Scale.38 A nonsignificant reduction as measured by the Barnes 
Akathisia Scale was also reported. In addition, patients 
showed a reduction in tardive dyskinesia as measured by the 
Abnormal Involuntary Movement Scale. However, it should 
be noted that patients in this study were able to switch to SOT 
after 1 week of ODO treatment if the treating physician felt 
that the patient had experienced significant improvement in 
psychosis and medication adherence, which occurred rela-
tively frequently (as noted above, 24 patients switched to 
SOT while 49 patients remained on ODO). For this reason, 
the improvements noted above may not be directly attribut-
able to the ODO formulation.
In contrast, Hori et al found no significant change in 
extrapyramidal symptoms over the course of their 4-week 
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study, although there was a numerical decrease relative to 
baseline as measured by the Drug-Induced Extrapyramidal 
Symptoms Scale (DIEPSS).36 Similar to Hori et al, Pascual 
et al also found no significant differences between ODO and 
conventional therapy groups on extrapyramidal symptoms 
as measured by the Udvalg for Kliniske Undersøgelser Side 
Effect Rating Scale. No movement disorders were spontane-
ously reported by patients.13 Thus, overall, extrapyramidal 
symptoms have tended to decline in some ODO studies and 
not differed significantly when directly compared with SOT.
Suicidality
In Czekalla et al’s study of ODO and SOT,30 52.6% of 
patients had some degree of suicidal ideation at baseline as 
measured by the mean score of item ten on the   Montgomery 
Asberg Depression Rating Scale. This included 6.6% of 
patients with distinct suicidal plans. The proportion of 
patients with some degree of suicidal ideation was found to 
similarly decrease from baseline after 2 weeks of therapy 
for both treatment groups (SOT from 51.2% to 22.7%; ODO 
from 53.9% to 20.6%). No patients with distinct suicidal 
plans were observed after 2 weeks in either treatment group. 
In Karagianis et al’s study, one patient (from the ODO group) 
attempted suicide.27 One completed suicide was reported by 
Bitter et al, although it was not reported which treatment 
group this patient belonged to at the time.28
Weight gain and metabolic profile
Weight gain and changes in metabolic parameters have 
been reported during treatment with atypical antipsychot-
ics, including olanzapine. Patients should be monitored at 
baseline and periodically during treatment. Long-term studies 
of olanzapine ($48 weeks; 573 days median) have demon-
strated a mean weight gain relative to baseline of 5.6 kg.44 
As mentioned earlier, ODO may be absorbed via the buccal 
mucosa or before reaching the pylorus (particularly when 
administered sublingually), and it has been hypothesized that 
this may lead to a different weight change profile compared 
with SOT.45 Further explanation of the hypothesis can be 
found in Karagianis et al’s review.45
Some support, albeit limited, for the above hypothesis 
initially came from some small/pilot studies and case reports 
which have predominantly included younger males with 
schizophrenia, indicating greater weight gain or absence of 
weight loss with SOT relative to ODO.35,46–49 For example, 
Arranz et al observed an increase in mean body weight over 
6 weeks of 6.3 ± 1.9 kg in SOT-treated patients compared 
with only 3.3 ± 3.2 kg in ODO-treated patients (P = 0.009).35 
  Substantial weight gain ($7% increase from baseline weight) 
was observed in 84.2% of SOT patients and in 31.6% of 
ODO patients in this study. Potential differences in the risk 
of weight gain and changes in metabolic parameters during 
treatment with ODO compared to SOT may impact treatment 
choice and patient adherence.
Studying this potential difference in weight gain, a 
  European research group recently conducted a small random-
ized crossover study in 12 healthy males to compare the short-
term metabolic profiles of ODO and SOT over 8 days.50 This 
study showed that although patients treated with olanzapine 
experienced changes in glucose and lipids, as well as weight 
gain, there were no significant differences between the ODO 
and SOT formulations in metabolic profile (homeostasis 
model of assessment of insulin resistance, fasting, and post-
prandial triglyceride and free fatty acid concentrations), body 
composition, fuel oxidation, or physical activity level, which 
may have explained potential differences in the weight gain 
profiles of the formulations.50 From this same study, it was 
also determined that patients treated with ODO and SOT had 
no consistent differences in changes in a variety of gut hor-
mones that may influence body weight.51 Moreover, studying a 
cohort of 23 patients with bipolar depression, Bobo et al used 
a randomized open-label design to compare ODO with SOT 
with regard to weight, BMI, fasting lipid, glucose, insulin, 
and leptin concentrations as well as two measures of eating 
attitude (Food Craving Inventory and Three-Factor Eating 
Questionnaire) over a longer timeframe of 8 weeks.52 With 
the exception of significantly lower triglyceride concentration 
in the ODO group at week 8, no other significant differences 
in metabolic profile or attitude towards food between the two 
formulations was found. However, it should be noted that in 
these studies, as with others, steps were not dictated in the 
protocol to ensure sublingual/pregut absorption of olanzap-
ine with the ODO formulation (for example, by prohibiting 
food and beverage consumption after administration). Thus 
under such circumstances, in some cases, olanzapine from 
ODO would be expected to reach the gut and behave in the 
same way as SOT. Therefore, validity of the hypothesis of 
possible weight differences being mediated by gut receptors 
remains uncertain.
Also, in contrast to the small supportive studies men-
tioned above, recent larger and more rigorous studies, 
while inconclusive, have not confirmed the hypothesis that 
ODO has a more favorable weight gain profile than SOT. In 
single-arm studies, weight gain with ODO has been similar 
to that seen with SOT. For example, patients in Kinon et al’s 
study gained 3.0 kg on average over 6 weeks (although, as 
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noted above, some of these patients switched to SOT after 
1 week, limiting the usefulness of the data in comparing 
the weight gain profiles of the formulations)38 and Hori 
et al found that weight (by 3.1 kg), BMI, plasma levels of 
triglycerides, and total cholesterol significantly increased,36 
although blood sugar levels did not significantly change. In 
Czekalla et al’s 2-week study,30 weight gain was reported as 
an adverse event by more ODO patients (2.8%) than SOT 
patients (1.0%). Also, in Bitter et al’s open-label crossover 
study,28 a similar degree of weight gain was observed for 
the two formulations (0.6 kg and 0.8 kg for SOT and ODO, 
respectively). In Chartier et al’s prospective observational 
study, no significant difference in weight gain was found 
between ODO and SOT over 12 months (schizophrenia: 
ODO 2.6 kg versus SOT 2.3 kg, P = 0.42; bipolar disorder: 
ODO 3.0 kg versus 2.5 kg, P = 0.54).32
A study that was designed to compare BMI and weight 
gain with ODO and SOT in healthy subjects over 3 weeks was 
recently stopped prematurely due to poor enrollment.53 As a 
consequence of the small number of patients who enrolled 
and took medication (ODO: N = 7; SOT: N = 9), there was no 
opportunity for meaningful analysis. Thus, while only indica-
tive, there was no evidence for significant group differences 
between ODO- and SOT-treated patients (ODO group gained 
3.3 kg on average versus 3.2 kg for SOT group).
In an attempt to resolve the question of whether ODO 
has a more favorable weight gain profile than SOT, a rigor-
ous double-blind double-dummy study was conducted by 
Karagianis et al.27 The PLATYPUS study, as it was named, 
failed (based on its primary endpoint) to confirm an advan-
tage for ODO over SOT on body weight and BMI as there 
was no significant difference between the two formulations 
in change from baseline in these measures after 16 weeks 
(primary analysis); ODO group gained 1.42 kg on average 
versus 2.08 kg for SOT group (P = 0.385). Moreover, the 
number of patients experiencing substantial weight gain 
(ODO: 14.6%, SOT: 11.1%) was not significantly differ-
ent between groups (P = 0.624). However, a significant 
group difference in adherence was observed whereby ODO 
patients were more likely to take their medication as indi-
cated, which may have impacted the incidence of weight 
gain in the ODO group due to greater and more prolonged 
antipsychotic exposure. Moreover, significant differences 
were detected in favor of ODO for prespecified categorical 
weight change distribution (the majority of ODO-treated 
patients gained ±1.0 kg, whereas the majority of SOT-treated 
patients gained 1.5–3.5 kg), and mean overall reduction in 
appetite (subjective measure by Visual Analog Scale) was 
significantly greater in ODO-treated patients. As pointed out 
by Karagianis et al, the analysis was not adjusted for these 
multiple secondary comparisons.
In order to investigate the possible confounding effect that 
adherence may have had on the original results,   Karagianis 
et al used data from the subset of adherent patients from 
the PLATYPUS study to investigate factors associated 
with weight gain during olanzapine treatment.54 This study 
found that the rate of weight gain slowed significantly more 
in patients switched from SOT to ODO compared to those 
continuing with SOT. Also, consistent with previous open-
label findings, weight gain was lower in males (but not 
females) and patients residing in the US (but not in Mexico 
or Canada) treated with ODO, compared with those treated 
with SOT. Given the posthoc and unpowered nature of these 
analyses, these exploratory results should be interpreted 
with caution.
The currently available evidence regarding a difference 
in the potential for weight gain with ODO versus SOT is 
inconsistent and warrants further study. However, what 
does seem apparent is that if a difference exists between 
formulations in this regard, it is not likely to be a substantial 
one and may manifest only in certain patient populations. 
It should also be borne in mind that equivalence of weight 
gain during olanzapine treatment should not be an overrid-
ing consideration if it comes at the cost of lower adherence 
and potential relapse.
Patient preference and medication 
adherence
Patient preference is an important factor in long-term treat-
ment adherence and thus treatment outcomes. Patients are 
more likely to persist with therapies they have had some 
active involvement in choosing, possibly aided by an 
enhanced therapeutic alliance as a consequence of improved 
patient motivation and insight into their illness and its 
treatment.28,55,56
One single-arm study provided data on patient   acceptance. 
Patients in Kinon et al’s study rated their acceptance of ODO 
using the Patient Global Impression Scale from one (I like 
it very much) to seven (I dislike it very much).38 Patient-
rated feelings about the medication showed positive accep-
tance of ODO at all measured time points (range in Patient 
Global Impression Scale scores: 2.01–2.74). Bitter et al 
also undertook an investigation into this important aspect 
of oral olanzapine formulation by comparing patients’ pref-
erence for ODO versus SOT in a randomized open-label 
crossover study.28 The primary finding of this study was 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
119
Orally disintegrating olanzapinePatient Preference and Adherence 2012:6
that   significantly more patients preferred ODO over SOT. 
Overall, 61% of patients preferred ODO, 27% preferred 
SOT, and 12% expressed no preference. Even taking into 
account a significant sequence effect with patients tending to 
prefer the last formulation they received, this result remained 
highly significant (P , 0.001). In other words, while patients 
preferred the last formulation that they had taken, this pref-
erence was not strong enough to overcome the formulation 
preference in favor of ODO. Common free-text responses by 
patients as reasons for preference for a specific formulation 
were ease of use, taste, expectation of better effectiveness, 
and weight change.
Medication nonadherence is an issue of significant clini-
cal importance in patients with serious mental illnesses such 
as schizophrenia and bipolar disorder. This is due to the fact 
that in these populations, the rate of nonadherence is high and 
is associated with poor outcomes such as low rates of remis-
sion and high rates of relapse, including hospitalization.57–62 
For example, patients who discontinue their medications have 
been found to have a monthly relapse rate of 11%, compared 
to that of 3.5% per month for patients who continue on main-
tenance treatment with conventional antipsychotic drugs.63 
Consequently, long-term outcomes such as quality of life 
and comorbid conditions may also be negatively affected by 
treatment nonadherence.64–67
In general, olanzapine studies utilizing SOT formulation 
have shown it to have an advantage in terms of treatment 
adherence and persistence over a number of typical and 
atypical antipsychotics.7,8,67–71 Despite the risk of weight gain 
during treatment with olanzapine, this adherence advantage 
may be largely conferred through its relatively favorable 
efficacy.1,2,72–75 It has been demonstrated that better adherence 
and persistence on antipsychotic medication is associated not 
only with better improvements in symptom severity76 and a 
higher level of functioning,77 but also with a significantly 
lower risk of psychiatric hospitalization.59,78–80
It appears that ODO may have an additional adherence 
advantage over SOT. The 16-week randomized double-blind 
double-dummy study by Karagianis et al found a signifi-
cantly higher proportion (92.9%) of patients on ODO being 
adherent (based on a pill count of at least 75% relative to 
that prescribed) compared with 78.5% of patients on SOT 
(P = 0.015).27 Since this was a blinded double-dummy study, 
this finding cannot be explained by physical differences in 
formulation. Karagianis et al suggested that the difference 
may be due to ODO possibly having some favorable effect, 
such as less appetite increase (or satiety failure), resulting in 
patients wanting to take medication more regularly.
The findings of Karagianis et al are augmented by data 
from various studies, some of which were single-arm stud-
ies showing significant improvement in patients’ adherence 
and/or attitudes toward medication intake with ODO. In a 
single-arm 6-week study of nonadherent patients who were 
switched to ODO,38 treatment adherence, as measured by 
the Treatment Compliance Interview and the nursing staff’s 
Nursing Assessment of Medication Acceptance (NAMA) 
compliance scale, had significantly improved from baseline 
to endpoint. Moreover, patients’ attitudes toward medica-
tion intake, per change in Rating of Medication Influences 
Noncompliance Score, also improved with a statistically 
significant reduction in this score within the first 2 days 
of therapy with ODO. Importantly, findings from these 
indirect and subjective measures of adherence (which may 
be   unreliable), were supported by measurement of patients’ 
olanzapine plasma concentration levels.38
There is additional evidence that treatment adherence may 
be further enhanced with ODO relative to SOT. Czekalla et al 
investigated the NAMA compliance scale as well as inges-
tion of ODO and SOT. They found that overall acceptance 
was lower for ODO at baseline (implying a potentially more 
noncompliant patient population to begin with), but ODO 
acceptance improved to a greater degree, almost reaching the 
same level as in SOT-treated patients, after 2 weeks.30
In Chartier et al’s prospective observational study, almost 
all patients on either ODO or SOT (95.3% on ODO, 93.7% 
on SOT) completed the 12-month study, showing a simi-
larly high persistence level on the medication.32 Although 
the two groups did not significantly differ regarding change 
from baseline in the Medication Adherence Rating Scale, 
ODO-treated patients were significantly less adherent to their 
antipsychotic medications at baseline and had less insight into 
their illness as measured by the Scale to Assess Unawareness 
of Mental Disorder.
In their preference study of ODO versus SOT, Bit-
ter et al also assessed medication adherence with the 
  Medication Adherence Form and found this measure to 
be similarly high for both formulations (ODO: 94%; SOT: 
93%; defined as adherent based on a score of .75% on 
the   Medication   Adherence Form).28 This finding was sup-
ported by tablet count (.98% patients deemed compliant 
for both   formulations). This study also found no significant 
differences between the treatment groups in change in atti-
tude towards treatment, as measured by the Drug Attitude 
  Inventory. Considering that patients included in this study 
had to be clinically stable and remained so throughout the 
study, this lack of significant difference in adherence may 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
Montgomery et alPatient Preference and Adherence 2012:6
result from this being an inherently adherent population of 
patients to begin with, thus having only minimal opportunity 
for further improvement in this regard.
When study design and differences in patient populations 
being compared are taken into consideration, overall, the 
above results suggest ODO is associated with similar, and 
likely improved, adherence compared with SOT. As ODO 
was designed for, and is often used in, patients with suspected 
or verified adherence problems, this should be reassuring for 
clinicians and should be considered when treating patients 
where opening a “therapeutic window,” in which greater 
insight and treatment adherence and/or persistence may lead 
to improved long-term outcomes, is a pivotal goal.
Nursing burden
Schizophrenia and bipolar disorder impose a significant 
work burden on nursing staff in inpatient treatment settings 
where treatment often needs to be administered under dif-
ficult circumstances and patients closely monitored on an 
ongoing basis. It would be expected that a treatment that is 
effective, well-tolerated, easy to administer, aids adherence, 
is well-accepted by patients, and whose administration can 
be verified would reduce nurses’ workload. In order to sys-
tematically investigate this important aspect of psychiatric 
treatment and quantify various aspects of nursing resource 
utilization, Eli Lilly and Company developed the NAMA 
scale. This scale is completed by nursing staff and mea-
sures patients’ acceptance and attitude towards medication, 
including burden of care on nursing staff.38 The NAMA 
questionnaire includes four items: (1) attitude (patient has a 
positive attitude towards medication), (2) compliance (patient 
complies with medication intake), (3) ingestion (patient 
ingests medication), and (4) nursing (no extensive nursing 
effort is needed to administer medication); a total score may 
also be calculated. Results relating to item two (compliance) 
were previously noted in the section on adherence. Due to its 
relevance to the intention of the ODO formulation, the scale 
has been used in a number of ODO studies.
Using NAMA, two single-arm studies have shown ODO 
to decrease nurses’ workload. Kinon et al used the NAMA 
questionnaire to assess nursing burden of treatment with 
ODO in acutely ill noncompliant patients with schizophrenia 
and schizoaffective disorder.38 Significant improvements in 
nursing burden were seen as early as day 2 and improve-
ments generally continued through to week 6. Hori et al also 
used the NAMA questionnaire to assess nursing burden in 
first-episode schizophrenia.36 NAMA total score decreased 
from 11.3 at baseline to 7.9 at day 28 (P , 0.01), with a 
significant decrease seen as early as day 7. Consistent with 
these results, without using NAMA, Van Heeringen et al 
investigated whether the use of ODO had an impact on 
  nursing workload or the need for intramuscular medication 
in a retrospective observational study in psychiatric inpatients 
and outpatients. They found that, based on physicians’ judg-
ment, use of ODO tablets reduced nurses’ workload in 64.6% 
of cases and intramuscular administration was avoided in 
65.1% of cases.39
In their large prospective observational study,   Czekalla 
et al used NAMA to assess nursing burden associated 
with ODO and SOT.30 Although a smaller proportion of 
patients showed positive medication acceptance towards 
ODO compared with SOT at the beginning of the study, 
a   proportionally higher number of patients showed a positive 
acceptance towards ODO at 2 weeks, resulting in a similar 
level of positive medication acceptance in ODO and SOT 
groups by this time. Thus, there is some evidence to suggest 
that ODO may not only reduce nursing burden relative to no 
treatment or other antipsychotics, but also when compared 
with SOT.
Clinical utility
What conclusions of clinical relevance can then be drawn 
from the existing data? The studies reviewed above included 
a broad range of patient populations representative of 
those seen in usual practice settings, including those with 
first-episode schizophrenia,36 patients already stabilized 
on treatment,22,28 patients with diagnoses of schizophrenia, 
schizoaffective, schizophreniform disorder, and bipolar 
disorder,27,38 and patients who are known to be nonadherent 
with treatment.38 These data have shown ODO to be a use-
ful addition to the standard oral tablet form of olanzapine 
which has similar pharmacokinetic, efficacy/effectiveness, 
tolerability, and characteristics. However, ODO formulation 
may have some advantages, not only where medical condi-
tions present swallowing difficulties for the patient with 
standard tablets (eg, dysphagia, stroke, gastroesophageal 
reflux disease) and in situations where access to liquids or 
discretion is needed, but also where rapid effect (eg, agitated 
patients in emergency settings) and/or where medica-
tion adherence is considered to be a potential concern or 
medication administration needs to be verified. Data from 
open-label naturalistic studies, where physicians were free 
to prescribe according to their usual practice, also indicates 
that when given the choice of ODO or SOT, they often (with 
some exceptions) selected ODO for the treatment of more 
severely symptomatic patients. In regards to the important 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
Orally disintegrating olanzapinePatient Preference and Adherence 2012:6
consideration of risk of weight gain during treatment with 
olanzapine, ODO may not have a significant advantage over 
SOT in all patients but at least does not appear to increase 
the risk of weight gain over SOT. Also, as there is a general 
preference amongst patients for ODO and it has been shown 
to reduce nurses’ workload, other than a potential cost differ-
ence in some countries, there seems to be little disincentive 
to offering patients this formulation over SOT as a matter of 
standard practice. However, the choice of ODO over SOT 
would seem particularly prudent when there is a change in 
treatment setting which may impact adherence, such as mov-
ing from a more controlled environment to a less controlled 
one, eg, discharge from an inpatient facility or change in 
caregiver or accommodation.
Limitations of existing ODO  
clinical data
Although there are a number of atypical antipsychotics in 
orally disintegrating formulations (eg, clozapine, risperidone, 
aripiprazole), very little information is available for those 
medications. On the other hand, limited as it is relative to 
SOT, more substantive data from across patient populations, 
world geographies, study types, and study measures is avail-
able from ODO studies. However, a number of limitations, 
as well as strengths, of the existing data need to be acknowl-
edged and taken into consideration.
With the exception of two large RCTs, the PLATYPUS 
study27 and Bitter et al’s preference study,28 the existing data 
reviewed in this article arises mostly from open-label and/or 
nonrandomized naturalistic studies. Each study design has its 
advantages and disadvantages which need to be considered in 
the interpretation of these results. In the case of randomized 
trials, this often involves the inclusion of only certain types of 
patients who meet strict selection criteria and who are willing 
to consent to a rigid study protocol. Moreover, study condi-
tions may not reflect real life practice conditions and, conse-
quently, it may not be appropriate to generalize the results of 
such studies to the broader population with the disease state 
under investigation. This may be the case with the preference 
study of Bitter et al,28 where patients needed to be stabilized 
on medication prior to entering the study. Also, patients in 
the PLATYPUS study must have already been stable, taking 
SOT, and experienced significant weight gain.27
While naturalistic observational studies have few 
inclusion criteria and are conducted under usual practice 
conditions, they are more representative of the types of 
outcomes that are to be expected in typical clinical practice. 
However, as patients tend to be allocated to medication the 
investigator believes is best suited to them, this inevitably 
leads to imbalance in various characteristics associated with 
treatment decisions (some of which may be unmeasured or 
unobserved), and may impact the final outcomes. Thus, in 
some ODO studies, patients with more severe symptoms who 
were considered less likely to be adherent with medication 
tended to be prescribed ODO. In such cases, comparing 
potential treatment effects in disparate patient groups may be 
misleading, even though some attempt may be made to adjust 
for this baseline imbalance using statistical methods. This 
difficulty is further complicated by the generally unrestricted 
use of concomitant medications and switching of treatments 
in naturalistic studies which makes linking outcomes with 
particular treatments more tenuous.
Regarding the apparent overrepresentation of observa-
tional research relative to RCT data in this review, it is worth 
bearing in mind that although RCTs are the gold standard in 
establishing the efficacy and safety of new therapeutic agents, 
observational research plays a valid role in filling the gap in 
knowledge between efficacy in highly selected patient groups 
in rigorously monitored/stringent settings and effectiveness in 
usual practice settings. The latter provides important insights 
into how the treatment actually performs and interacts with 
various patient characteristics, comorbidities, and concomi-
tant medications which are not necessarily present in clini-
cal trials, yet is the environment in which the treatment will 
ultimately be used. This distinction is particularly important 
when considering the actual use and patient population which 
ODO could benefit (ie, those that would typically not be rep-
resented in RCTs). There would also be little value replicating 
the efficacy of ODO in highly controlled clinical trials when 
efficacy has already been established with SOT, as the active 
ingredient, olanzapine, is the same.
The main purpose of the ODO formulation has not been 
to alter the active ingredient but rather to enhance its palat-
ability, ease of ingestion, convenience, and acceptability in 
patients, particularly those difficult-to-treat patients with 
swallowing problems or adherence issues. These aspects 
of pharmacological treatments are elusive to conventional 
RCT designs as they either exclude patients with such issues 
(despite their prevalence in the community) or are overridden 
by the study design (patients who do not take the medication 
as directed are usually discontinued/excluded from analysis 
and so factors such as convenience and patient preference 
are largely ignored). It is thus entirely understandable and 
to be expected that, with the exception of the PLATYPUS 
study which aimed to answer a very specific question, the 
focus of ODO research has not been the use of randomized 
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clinical   trials and replicating efficacy findings, but rather in 
the conduct of observational research to gain a better under-
standing of the benefits and limitations of the formulation in 
the actual target population under realistic conditions.
Another feature of the reviewed studies that complicates 
interpretation of the results is the tendency to conduct a 
multitude of secondary analyses, most of which were not 
sufficiently powered to assess the question at hand. Thus, 
nonsignificant results of the secondary analyses may arise 
from type II (false negative) error, whereas differences 
deemed significant on this basis may be consequence of 
type I (false positive) error.
Overall, while these studies provide a wealth of valuable 
information, in many cases the findings need to be replicated 
independently before they can be accepted as conclusive.
Conclusion
The literature reviewed in this article regarding the physi-
cal characteristics, efficacy/effectiveness, tolerability, and 
safety profile of ODO lend support to this formulation being 
a useful alternative to SOT, particularly in situations where 
patient adherence is problematic or verification of ingestion is 
needed, where the patient’s ability to swallow standard tablets 
is compromised, and where other formulations (eg, injection) 
are resisted or considered undesirable. The existing data sug-
gests that although having a similar efficacy and tolerability 
profile to SOT, long-term patient outcomes may be improved 
with ODO in some patients due to better adherence, leading 
to lower relapse/hospitalization risk. ODO may also have 
benefits over SOT in terms of nursing burden and patient 
preferences, and this should be taken into consideration when 
making treatment decisions. While other rapidly dissolving 
generic formulations of olanzapine are available in various 
countries around the world, given the ostensibly important 
role of physical characteristics in determining patient prefer-
ence and adherence, the recent comparative dissolution study 
of Hobbs et al26 suggests that the majority of findings (other 
than bioequivalence) reviewed here may not necessarily be 
extrapolated to these other formulations.
In summary, taking into consideration the known efficacy 
and tolerability profile of olanzapine combined with the 
greater adherence potential of ODO, apparently influenced 
by patient preference considerations and rapid onset of effi-
cacy which further enhances insight and patient acceptance 
of medication, this formulation is not only suitable for the 
majority of patients, but may be particularly useful in opening 
a “medication gateway” to some difficult-to-treat nonadher-
ent patients.
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